Steve Schonfeld’s PDL BioPharma, Inc. PDLI Stock Holding History

Steve Schonfeld’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-18,656	Closed	-$59K	–	1368
2019 Q2	$59K	Buy	+18,656	New	+$60.5K	﹤0.01%	940
2018 Q1	–	Sell	-13,069	Closed	-$36K	–	1084
2017 Q4	$36K	Buy	+13,069	New	+$40.1K	﹤0.01%	720

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Steve Schonfeld's PDLI Position: Q3 2019 in Review

Steve Schonfeld sold out of PDL BioPharma, Inc. (PDLI) in Q3 2019, closing a stake of 18,656 shares — an estimated $59K sold.

Steve Schonfeld first reported a position in PDLI in Q4 2017 and held it in 2 quarters. The position peaked at $59K in Q2 2019. 140 funds tracked by Wall St. Rank hold PDLI as of Q3 2019.

Steve Schonfeld reported no remaining PDL BioPharma, Inc. position as of Q3 2019 after selling out during the quarter.
Steve Schonfeld sold 18,656 PDL BioPharma, Inc. shares in Q3 2019, an estimated $59K.
Steve Schonfeld first reported a position in PDL BioPharma, Inc. in Q4 2017 and held it in 2 quarters.
Steve Schonfeld's PDL BioPharma, Inc. position peaked at $59K in Q2 2019.
140 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2019.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.